Ibogaine for Healthy Volunteers

2 papers and 1 clinical trial exploring ibogaine as a treatment for healthy volunteers.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile

IndicationApproximately 300 million people affected by depression worldwide.

Healthy Volunteers

Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.

Full Healthy Volunteers profile

Academic Research

2 papers

Paywallindividual

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers

This open-label study (n=21) investigated the pharmacokinetics of a single dose of ibogaine (20mg) in response to inhibiting its metabolism via pretreatment with the antidepressant paroxetine in a placebo-controlled manner. Results indicate that the dose was safe and well-tolerated in all subjects, although paroxetine greatly increased the half-life of ibogaine to detectable levels at 72 hours post-infusion.

Published: February 25, 2015
Journal: Journal of Clinical Pharmacology
Authors: Garbe, K., Glue, P., Hung, C. T., Jakobi, H., Lenagh-Glue, Z., Lyudin, A., Winter, H.

Paywallindividual

Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability

This ascending single-dose, placebo-controlled, randomised, double-blind, parallel-group study (n=36) investigated the safety and pharmacokinetic profile of orally ingested noribogaine (3, 10, 30, or 60mg), and found that it was rapidly absorbed and slowly eliminated, and generally safe and well-tolerated in healthy male volunteers.

Published: December 22, 2014
Journal: Journal of Clinical Pharmacology
Authors: Friedhoff, L., Glue, P., Hung, C. T., Hung, N., Lam, F., Lockhart, M.

Clinical Trials

1 trial

CompletedPhase I

The role of CYP2D6 in the pharmacokinetics of ibogaine in healthy volunteers

This randomised, double-blind, placebo-controlled trial (n=24) investigates the role of CYP2D6 in the pharmacokinetics of ibogaine (20mg) in healthy volunteers.

Started: July 1, 2013
Type: interventional
Blinding: single
Randomized: Yes
Registry ID: ACTRN12613000324718

Explore further

Search all Ibogaine papers Search all Healthy Volunteers trials Full Ibogaine profile Full Healthy Volunteers profile